The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on () and its flagship drug Lupuzor - a treatment for the autoimmune disease Lupus.
Dr Malik says despite not meeting its primary end point in a recent phase III trial, the response rate overall compares well to a number of other pivotal studies and has an excellent safety profile.
Worldwide, there are 5mln people with Lupus, 1.5mln of them in the US, Europe and Japan.
Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event,
London , 05 September 2019.
Register here »